New randomized Phase 1 trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe.
from Medindia Health News https://ift.tt/3snTODz
No comments:
Post a Comment